Samsung JV may not be in Biogen's long term plans

Biogen Inc. (NASDAQ:BIIB) management said staying in its Samsung Bioepis JV with Samsung BioLogics Co. Ltd. (KSE:207940) may not be in its long-term plans. The comments about the biosimilars JV formed in 2012 were made May 30 at the Bernstein Strategic Decisions Conference.

Biogen owns about a 5% stake in Bioepis and maintains an option to increase its holdings in the JV to 49.9%. In April, Biogen CFO and EVP Jeff Capello said the company plans to exercise the option, which expires in mid-2018...